Claims

1. A compound of Formula (I), or a salt thereof,



(I)

wherein

A_1 is CH;

A_2 is selected from CR_{13} and N;

R_1 is selected from C_4-C_7heterocycloalkyl, or

C_5-C_6heteroaryl, wherein

C_4-C_7heterocycloalkyl, and C_5-C_6heteroaryl are optionally substituted with one to three groups independently selected from hydroxy, methoxy, C_1-C_3alkyl and halo;

L_1 is a linker group selected from -C(O)- and -$S(O)_n$-, wherein n represents 1 to 2;

R_3 is selected from hydrogen, halo, methyl, methoxy and cyano;

R_4 is selected from hydrogen, halo, methyl, methoxy and cyano;

R_2 is selected from hydrogen, halo, Ar, Cy, X, $NR_{5a}R_{5b}$ and -C(O)-R_{15};

Ar is selected from phenyl and C_5-C_6heteroaryl, each of which is optionally substituted with one to three groups independently selected from halo and -L_2-$R_{7;}$

L_2 is a linker group selected from a bond, -$(CH_2)_m$-, -$O(CH_2)_m$-, -C_2-C_4alkenyl-, -OC_2-C_4alkenyl-, -$(CH_2)_p$-NH-$(CH_2)_q$-, and -$(CH_2)_p$C(O)-$(CH_2)_q$-; wherein m represents 1 to 4 and p and q independently represent 0 to 4;

R_7 is selected from hydrogen; hydroxy; $NR_{8a}R_{8b;}$ C_4-C_7heterocycloalkyl optionally substituted with one or two C_1-C_3alkyl groups; C_3-C_7cycloalkyl; C_1-C_6alkoxy optionally substituted with one $NR_{14a}R_{14b}$ group; and phenyl optionally substituted with one to three groups independently selected from halo, methoxy and methyl;

Cy is selected from C_3-C_7cycloalkyl, C_4-C_7heterocycloalkyl, C_5-C_7cycloalkenyl and C_5-C_7heterocycloalkenyl, each of which is optionally substituted with one to three groups independently selected from C_1-C_3alkyl, C_1-C_3alkoxy, C_4-C_7heterocycloalkyl, $NR_{11a}R_{11b}$, =O, -C(O)-R_{15} and -C(O)O-R_{15};

X is selected from C_1-C_6alkyl, C_2-C_6alkenyl and C_1-C_6alkoxy, each of which is optionally substituted with one to three groups independently selected from hydroxy, methoxy, halo, $NR_{13a}R_{13}$b and C_4-C_2heterocycloalkyl, wherein C_4-C_2heterocycloalkyl is optionally substituted with one to three C_1-C_3alkyl groups;

R_{5a} is selected from hydrogen; C_1-C_6alkyl optionally substituted with one group selected from Ar and Cy; -C(O)-R9; -C(O)-OR_9; and -SO_2-R_9;

R_{5b} is selected from hydrogen and C_1-C_3alkyl;

R_{8a} and R_{8b} are independently selected from hydrogen and C_1-C_3alkyl;

R_9 is selected from C_1-C_6alkyl, C_3-C_2cycloalkyl, C_4-C_2heterocycloalkyl, phenyl and C_5-C_6heteroaryl;

R_{10a} and R_{10b} are independently selected from hydrogen and C_1-C_3alkyl;

R_{11a} and R_{11b} are independently selected from hydrogen and C_1-C_3alkyl;

R_{12} is selected from hydrogen, halo and methyl;

R_{13} is selected from hydrogen, C_1-C_3alkyl, -C(O)-C_4-C_2heterocycloalkyl, -C(O)-C_1-C_3alkyl and -C(O)-C_3-C_7cycloalkyl;

R_{13a} and R_{13b} are independently selected from hydrogen and C_1-C_3alkyl;

R_{14a} and R_{14b} are independently selected from hydrogen and C_1-C_3alkyl; and

R_{15} is selected from C_1-C_6alkyl, Ar, C_3-C_2cycloalkyl and C_4-C_2heterocycloalkyl.

2. A compound according to claim 1, wherein R_1 is C_4-C_2heterocycloalkyl optionally substituted with one C_1-C_3alkyl or with one or two halo.

3. A compound according to claim 1 or claim 2, wherein L_1 is -C(O)-.

4. A compound according to any one of claims 1 to 3, wherein R_2 is selected from hydrogen, halo, Ar, Cy, and X.

5. A compound according to any one of claims 1 to 4, wherein R_2 is Cy and Cy is C_4-C_2heterocycloalkyl.

6. A compound according to any one of claims 1 to 5, wherein R_3 is hydrogen or halo and R_4 is hydrogen, halo, or methyl.

7. A compound of Formula (I) according to claim 1, which is



8. A compound of Formula (IA), or a salt thereof,



(IA)

wherein

A_1 is CH;

A_2 is selected from CR_{13} and N;

R_1 is selected from C_4-C_7heterocycloalkyl, or,

C_5-C_6heteroarylwherein C_4-C_7heterocycloalkyl, and, C_5-C_6heteroaryl are optionally substituted with one to three groups selected from hydroxy, methoxy, C_1-C_3alkyl and halo;

L_1 is a linker group selected from -C(O)- and -$S(O)_n$-; wherein n represents 1 to 2;

R_3 is selected from hydrogen, halo, methyl, methoxy and cyano;

R_4 is selected from hydrogen, halo, methyl, methoxy and cyano;

R_2 is selected from hydrogen, halo, Ar, Cy, X and $NR_{5a}R_{5b}$;

Ar is selected from phenyl and C_5-C_6heteroaryl, each of which is optionally substituted with one to three groups independently selected from $NR_{6a}R_{6b}$ and - L_2-R_2;

L_2 is a linker group selected from a bond, -$(CH_2)_m$-, $^{-}O(CH_2)_m$-, -C_2-C_4alkenyl- and -OC_2-C_4alkenyl-; wherein m represents 1 to 4;

R_7 is selected from hydrogen, C_4-C_7heterocycloalkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, hydroxy and $NR_{8a}R_{8b}$;

Cy is selected from C_3-C_2cycloalkyl, C_4-C_2heterocycloalkyl, C_5-C_2cycloalkenyl and C_5-C_2heterocycloalkenyl, each of which is optionally substituted with one to three groups independently selected from C_1-C_3alkyl, C_4-C_2heterocycloalkyl and NR11aR11b;

X is selected from C1-C6alkyl, C_2-C_6alkenyl and C_1-C_6alkoxy, each of which is optionally substituted with one to three groups independently selected from hydroxy, methoxy, halo and C_4-C_2heterocycloalkyl, wherein C_4-C_2heterocycloalkyl is optionally substituted with one to three C_1-C_3alkyl groups;

R_{5a} is selected from hydrogen, C_1-C_6alkyl, -C(O)-R_9, -C(O)-OR_9 and -SO_2-R_9;

R_{5b} is selected from hydrogen and C_1-C_3alkyl;

R_{6a} and R_{6b} are independently selected from hydrogen and C_1-C_3alkyl;

R_{8a} and Rsb are independently selected from hydrogen and C_1-C_6alkyl;

R_9 is selected from C_1-C_6alkyl, C_3-C_2cycloalkyl, C_4-C_2heterocycloalkyl, phenyl and C_5-C_6heteroaryl;

R_{10a} and R_{10b} are independently selected from hydrogen and C_1-C_3alkyl;

R_{11a} and R_{11b} are independently selected from hydrogen and C_1-C_3alkyl;

R_{12} is selected from hydrogen, halo and methyl; and

R_{13} is selected from hydrogen and C_1-C_3alkyl.

9. A compound of Formula (I) or (IA) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising (a) a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier.

11. A combination comprising (a) a compound of Formula (I) or (IA) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and (b) at least one additional therapeutic agent.

12. A compound of Formula (I) or (IA) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use in therapy.

13. A compound of Formula (I) or (IA) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a parasitic disease selected from Chagas disease, Human African Trypanosomiasis, Animal African trypanosomiasis and leishmaniasis.

14. Use of a compound of Formula (I) or (IA) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a parasitic disease selected from Chagas disease, Human African Trypanosomiasis, Animal African trypanosomiasis and leishmaniasis.

15. A compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, for use according to claim 13, wherein the leishmaniasis is visceral leishmaniasis.

16. Use of a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, according to claim 14, wherein the leishmaniasis is visceral leishmaniasis.